Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma
<b>Background/Objectives:</b> Neurofibromatosis Type 1 (NF1) plexiform neurofibroma (PN) can cause morbidity, including disfigurement that can negatively impact social functioning. Historically, the mainstay treatment is surgical resection. However, complete resection is often prohibitiv...
Saved in:
| Main Authors: | Carlen A. Yuen, Eleanor Chu, Ryan O’Connell, Bryan K. Sun, Raj Vyas, Michelle Zheng, Emma Elliott, Changrui Xiao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/7/1039 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects for diagnostics and treatment of neurofibromatosis type 1 in Russia
by: R. N. Mustafin
Published: (2023-06-01) -
Rare case of primary neurofibroma involving urinary bladder without signs of neurofibromatosis: An "Oddball" to urologist
by: Ajaykumar Dhirubhai Tadha, et al.
Published: (2023-09-01) -
Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1
by: Pernelle Pulh, et al.
Published: (2025-07-01) -
Therapeutic drug monitoring of selumetinib in pediatrics: a combined LC-MS/MS and LC-HRMS approach
by: Alessia Cafaro, et al.
Published: (2025-08-01) -
Clinical Masks of Neurofibromatosis Type 1
by: R. N. Mustafin
Published: (2022-03-01)